Literature DB >> 33658218

Intrahepatic cholangiocarcinoma in a non-cirrhotic liver in a patient with homozygous ZZ alpha-1 antitrypsin deficiency.

Nienke E Vuurberg1, Anne Loes Van den Boom2, Marius C Van den Heuvel3, Joost M Klaase2.   

Abstract

Alpha-1 antitrypsin (AAT) deficiency, which is an under-recognised metabolic genetic disorder, is known to cause severe lung disease and liver cirrhosis in about 10%-15% of cases. Patients with AAT deficiency are at a higher risk for developing hepatocellular carcinoma, both in cirrhotic and in non-cirrhotic livers. In this case report, a 48-year-old woman with homozygous ZZ AAT deficiency presented with abdominal pain, and by imaging, an abnormal area in the liver was found. The initial differential diagnosis consisted of benign abnormalities but a malignancy could not be ruled out. Finally, this abnormality turned out to be an intrahepatic cholangiocarcinoma (iCCA) in a non-cirrhotic liver. Since this type of tumour has been very infrequently described to be associated with AAT deficiency, the question remains whether alpha-1 trypsin accumulation in the hepatocytes was responsible for the development of iCCA. However, other associated factors for developing an iCCA were ruled out. © BMJ Publishing Group Limited 2021. Re-use permitted under CC BY. Published by BMJ.

Entities:  

Keywords:  hepatic cancer; liver disease; surgery; surgical oncology

Mesh:

Substances:

Year:  2021        PMID: 33658218      PMCID: PMC7931763          DOI: 10.1136/bcr-2020-240077

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  13 in total

1.  Intrahepatic cholangiocarcinoma.

Authors:  Kimberly M Brown; Abhishek D Parmar; David A Geller
Journal:  Surg Oncol Clin N Am       Date:  2014-04       Impact factor: 3.495

2.  Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma?

Authors:  H Zhou; M E Ortiz-Pallardó; Y Ko; H P Fischer
Journal:  Cancer       Date:  2000-06-15       Impact factor: 6.860

Review 3.  The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.

Authors:  Robert A Sandhaus; Gerard Turino; Mark L Brantly; Michael Campos; Carroll E Cross; Kenneth Goodman; D Kyle Hogarth; Shandra L Knight; James M Stocks; James K Stoller; Charlie Strange; Jeffrey Teckman
Journal:  Chronic Obstr Pulm Dis       Date:  2016-06-06

4.  Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma.

Authors:  F Mihalache; A Höblinger; F Grünhage; M Krawczyk; B C Gärtner; M Acalovschi; T Sauerbruch; F Lammert; V Zimmer
Journal:  Aliment Pharmacol Ther       Date:  2010-12-08       Impact factor: 8.171

5.  BRAF V600E mutation in biliary proliferations associated with α1 -antitrypsin deficiency.

Authors:  Napat Angkathunyakul; Francesca Rosini; Nigel Heaton; Pierre Foskett; Alberto Quaglia
Journal:  Histopathology       Date:  2016-11-15       Impact factor: 5.087

Review 6.  Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy.

Authors:  Jeffrey H Teckman
Journal:  COPD       Date:  2013-03       Impact factor: 2.409

Review 7.  The current management of cholangiocarcinoma: A comparison of current guidelines.

Authors:  Yulong Cai; Nansheng Cheng; Hui Ye; Fuyu Li; Peipei Song; Wei Tang
Journal:  Biosci Trends       Date:  2016-03-29       Impact factor: 2.400

Review 8.  Pathogenesis, diagnosis, and management of cholangiocarcinoma.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  Gastroenterology       Date:  2013-10-15       Impact factor: 22.682

Review 9.  Hereditary alpha-1-antitrypsin deficiency and its clinical consequences.

Authors:  Laura Fregonese; Jan Stolk
Journal:  Orphanet J Rare Dis       Date:  2008-06-19       Impact factor: 4.123

10.  Liver disease in adults with severe alpha-1-antitrypsin deficiency.

Authors:  Hanan A Tanash; Eeva Piitulainen
Journal:  J Gastroenterol       Date:  2019-01-24       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.